Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2015

View Archived Issues

Colonic release formulations of linaclotide under study in phase IIb trial

Amgen releases update from third quarter 2015

Highlights from ERS 2015

hVIVO invests in start-up company PrEP Biopharm

Sanofi profiles regulatory and development activities of third quarter 2015

Eisai reviews achievements of second quarter of fiscal 2015

Innate initiates phase I study of IPH-4102 in CTCL

NR-11/194: a potent CCR9 receptor antagonist

AS-002 shows preventative and curative effect in UC

ViiV Healthcare and Janssen report results from injectable cabotegravir regimen study

CJ Healthcare presents GPR40 agonists

Advances in siRNA therapeutic technology

OliX Pharmaceuticals discloses its cell-penetrating asymmetric siRNA technology

Tocopherol-conjugated DNA/RNA heteroduplex oligonucleotides enhance brain and liver targeting

BriaCell receives FDA approval to begin phase I/IIa trial of BriaVax

FDA grants orphan drug designation to AGIL-AS for Angelman syndrome

Institut Pasteur Korea and Terramark Markencreation disclose anti-HCV agents

Sunshine Lake Pharma patents 5-HT6 receptor antagonists

Takeda Pharmaceutical reports CDK8/19 inhibitors

Millennium Pharmaceuticals presents Nampt inhibitors

Ratiopharm introduces monomethyl fumarate prodrugs

Johnson & Johnson to acquire Novira Therapeutics

FDA grants fast track designation to long-acting buprenorphine for opioid addiction

FDA first to approve GlaxoSmithKline's Nucala

Phase II study of AQX-1125 in atopic dermatitis does not meet primary endpoint

Sanofi and Hanmi partner to develop long-acting diabetes treatments

FDA grants fast track designation to Paratek's omadacycline for ABSSSI, CABP and cUTI

Health Canada approves Cingal for osteoarthritis knee pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...